Blog

A Major Step Toward Precision Diagnostics with the Implementation of CaloPix®

PARIS, FRANCE / ACCESS Newswire / July 3, 2025 / Tribun Health, European leader in AI-enhanced digital pathology, is proud to announce that the Versailles Hospital Center, the supporting institution of GHT 78 Sud, has selected its imaging platform, CaloPix®, to support the digital transformation of its pathology department.

This decision represents a strategic milestone in modernizing diagnostic services within the French public healthcare system. Through this project, the Versailles Hospital Center joins a growing network of pioneering institutions leveraging Tribun Health’s technologies to optimize workflows, enhance diagnostic quality, and prepare for the integration of artificial intelligence.

“We are honored by the trust that the Versailles Hospital Center has placed in us,” said Jean-François POMEROL, CEO of Tribun Health. “This choice reflects a shared commitment to innovating for more effective, collaborative, and patient-centered healthcare.”

“The selection of CaloPix® is fully aligned with our digital transformation strategy,” explained Dr. Claire GLASER, Head of the Pathology Department at the Versailles Hospital Center. “We were impressed by the solution’s user-friendliness, performance, and the quality of support offered by Tribun Health’s teams. This project, developed in collaboration with the GHT Yvelines Nord, marks a key step for the future of our specialty in the region, particularly regarding AI and collaborative work. It also enhances our integration into APHP’s expert networks equipped with the same software.”

CaloPix® will be deployed throughout the pathology department to support primary diagnostics, interdisciplinary collaboration, and the future integration of AI solutions. Known for its intuitive interface, high performance, and adaptability to the evolving needs of hospital structures, the platform is open and interoperable.

This project is fully aligned with the digital strategy of the Versailles Hospital Center and GHT 78 Sud, in collaboration with GHT Nord, and reflects a national plan aimed at modernizing and digitizing healthcare infrastructures. It is also part of a strong regional initiative and will serve as an interoperability foundation within the GHTs of the Yvelines region.

About Tribun Health

Tribun Health, recognized under the French Tech 2030 label, is a global leader in digital pathology, offering award-winning solutions that improve workflow efficiency, diagnostic accuracy, and patient outcomes. We assist hospitals and laboratories in transitioning from glass slide pathology to fully digital solutions, leveraging AI and data-driven technology to enhance precision and reduce turnaround times. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovations, we are shaping the future of cancer care. For more information, visit Tribun Health and follow us on LinkedIn and X.

Contact Information

Andreia Beyer
VP, Global Marketing & Managing Director, North America
abeyer@tribun.health
+1 (416) 565-0474

SOURCE: Tribun Health

View the original press release on ACCESS Newswire

With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets

MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company’s proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation.

Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects.

“These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential,” said Erez Aminov, Chairman and CEO of MIRA. “We believe the drug’s ability to match morphine’s pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It’s another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain.”

Study Overview and Key Findings

Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat’s paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume.

Key findings:

• Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline levels.

• Its analgesic effect was equivalent to morphine, the standard opioid comparator in the study.

• No sedation or inflammatory swelling was observed with Mira-55 treatment.

Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound’s long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development.

These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55’s selective pharmacological profile.

“Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs,” said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. “Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today’s standards.”

Strategic Fit Within MIRA’s Pain Portfolio

Mira-55 complements Ketamir-2, MIRA’s clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain.

“With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated,” added Aminov. “We’re advancing each asset methodically, and we’re energized by the momentum we’ve built across the pipeline.”

Corporate Update on SKNY Merger

MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction.

“We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation,” said Aminov. “This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth.”

Next Steps

MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones.

About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

Path of Liberty will offer active, off-duty, and retired military members and their families special complimentary tickets for prime viewing.

NEW YORK, NY / ACCESS Newswire / July 2, 2025 / Path of Liberty: That Which Unites US, a powerful public art installation made possible by The Soloviev Foundation, will welcome active, off-duty, and retired military members and their families this Independence Day at 8:30pm as the nation begins the official countdown to America’s 250th birthday. Situated along the East River, the installation offers a meaningful backdrop for the celebration and live simulcast of the annually anticipated Macy’s Fireworks Show. To reserve complimentary tickets for this private catered event, please visit poljuly4.splashthat.com.

LEFT: Path of Liberty: That Which Unites US, an immersive public art installation at Freedom Plaza made possible by the Soloviev Foundation, features larger-than-life photography and videos of Americans from across the country. Courtesy of C&G Partners, Exhibition and Experience Designer.

RIGHT: Lieutenant Mickey Kross is a retired New York City firefighter whose miraculous survival during the September 11, 2001 attacks has become a powerful testament to resilience and courage. A member of Engine Company 16, Kross was assigned to the North Tower that morning. He and his team had reached the 23rd floor to assist with evacuations when the South Tower collapsed. Moments later, as the North Tower began to fall, Kross was buried beneath the rubble. Trapped for nearly three hours, he survived by taking shelter in a corner, with his helmet shielding him from falling debris. In the aftermath, Kross played an active role in the recovery efforts at Ground Zero. The helmet that helped save his life is now preserved in the National September 11 Memorial & Museum, serving as a symbol of bravery and endurance. Courtesy of The Soloviev Foundation.

High resolution installation and subject images can be downloaded here

“This year’s 4th of July begins a historic journey toward America’s 250th birthday,” said Michael Hershman, a decorated Army veteran and CEO of Soloviev Group. “We are proud that Path of Liberty offers a space where neighbors, veterans, and visitors can come together to reflect on our shared values and honor the diverse voices that continue to shape our country.”

Stretching from 38th to 41st Street along First Avenue, the six-acre immersive installation transforms the cityscape with a larger-than-life tribute to the founding ideals that unite us. With vibrant visuals and emotional storytelling, Path of Liberty: That Which Unites US offers a fresh and inclusive lens on what it means to be American.

The installation, by exhibition and experience design firm C&G Partners and directed by Cannes-selected filmmaker Daniella Vale, features 41 towering interactive screens showcasing striking photography and short films. This brings to life the personal stories of 55 Americans – veterans, librarians, farmers, Indigenous leaders, astronauts, and others-whose lived experiences illuminate the shared principles of liberty, equality, and perseverance.

The exhibit is free and open to the public every Thursday through Saturday from 8:00 PM to 11:00 PM, with walk-ups welcome and advance reservations available at pathoflibertynyc.com.

Path of Liberty: That Which Unites US expands on The Soloviev Foundation’s commitment to bringing the community together through art that encourages contemplation, nurtures connection, and inspires hope.

TOP LEFT: Petty Officer 1st Class Steven Edgar is a Mass Communication Specialist in the U.S. Navy, stationed at Naval Air Station Joint Reserve Base (NAS JRB) New Orleans. In this role, he produces and manages public affairs content, including photography, videography, and written communications that highlight the base’s missions and personnel. Courtesy of The Soloviev Foundation.

TOP RIGHT: Ariel Broussard is a dedicated service member in the U.S. Navy, currently stationed in New Orleans. With a strong commitment to national service, Broussard plays a vital role in supporting the Navy’s operations while contributing to the city’s vibrant military community. Courtesy of The Soloviev Foundation.

BOTTOM LEFT: Noah Currier is a decorated Marine veteran and the founder of Oscar Mike, a nonprofit dedicated to supporting disabled veterans through mental health services and adaptive sports. After returning from Iraq, Currier sustained a life-changing spinal cord injury in a vehicle accident. Rather than letting adversity limit him, he turned his experience into a mission to uplift fellow veterans. Through Oscar Mike, he provides rehabilitation and empowerment programs that help wounded service members regain their independence and sense of purpose. Courtesy of The Soloviev Foundation.

BOTTOM RIGHT: Al “Mr. G” Godlewski enlisted in the Army during World War II in 1943, serving in England and France with the 140th Finance Disbursement Section. He narrowly escaped a torpedo attack and played a key role in ensuring 30,000 soldiers received their pay. Now at 100 years old, he remains active, enjoying time with family, reading, jigsaw puzzles, and the occasional martini. Courtesy of The Soloviev Foundation.

ABOUT PATH OF LIBERTY: THAT WHICH UNITES US

Encompassing more than six-acres on Manhattan’s East Side from 38th to 41st Street on First Avenue, the large-scale exhibition provides a visual and narrative journey of the founding principles of the United States, framed by stunning portraits and immersive landscapes. Made possible by the Soloviev Foundation, Path of Liberty: That Which Unites US will welcome guests and present an exploration of both the achievements and ongoing challenges of American democracy. Through powerful, large-scale environmental portraits and interactive elements, visitors will leave with a deeper understanding of the country’s past, present, and future. Please visit pathoflibertynyc.com and follow @pathoflibertynyc on Instagram and Facebook for more information.

ABOUT THE SOLOVIEV FOUNDATION

The Soloviev Foundation is the charitable giving arm of the Soloviev Group, dedicated to supporting the efforts of those working across humanitarian, environmental, and educational causes. The Foundation’s gifts go to both large, long-established institutions addressing global crises and concerns, and smaller, hyperlocal organizations serving the populations in need within their communities. For more information, visit solovievfoundation.org.

Contact Info:
info@dujour.com
646-710-4494

SOURCE: DuJour Media

View the original press release on ACCESS Newswire

Well-Known Entrepreneur Hired for Key Leadership Role

SCOTTSDALE, ARIZONA / ACCESS Newswire / July 2, 2025 / Phone Ninjas, the automotive industry’s leader in dealership-specific coaching and training, is proud to spotlight Ashley Vlastaris, one of the newest additions to its growing team of Sales Executives. In just five months, Ashley has already made a strong impression, bringing fresh energy, a dealer-first mindset, and a relentless focus on driving measurable results.

“Ashley really hit the ground running,” said Chris Vitale, Chief Operating Officer at Phone Ninjas. “From day one, she’s been deeply engaged with our dealer partners, asking the right questions, listening carefully, and working hard to understand each store’s unique challenges. That curiosity and drive are exactly what make a great Sales Executive.”

Already, she’s been instrumental in supporting dealership sales teams, understanding showroom dynamics, and helping tailor training solutions that improve performance metrics like appointment set, show, and buy rates.

“When you’re working with dealers, it’s not about selling a product – it’s about solving problems,” said Ashley. “They’re busy, they’re juggling priorities, and they need real support. That’s what drew me to Phone Ninjas – we’re not here to add noise; we’re here to make things work better.”

As Phone Ninjas continues its rapid expansion, team members like Ashley represent the next generation of automotive coaching, bringing passion, data-savvy insight, and an unwavering commitment to dealer success.

About Phone Ninjas

Founded in 2010, Phone Ninjas helps businesses master all client-facing communications with one goal in mind: better conversations that lead to better results. Through expertly designed ongoing coaching and training programs that support the sales, service, and parts departments, Phone Ninjas helps dealers turn all client interactions into appointments that show and buy – the right way.

SOURCE: Phone Ninjas

View the original press release on ACCESS Newswire

SAN RAMON, CA / ACCESS Newswire / July 2, 2025 / CMG Financial, one of the nation’s top mortgage lenders, is proud to announce that two of its Executive Vice Presidents, Courtney Thompson and Susan Walker, have been named to HousingWire’s 2025 Women of Influence list. This prestigious award honors women in housing who are making notable contributions to both their organizations and the industry at large. With their innovative thinking, leadership, and vision for the future, Courtney and Susan exemplify what it means to lead with impact.

“This year’s honorees include mentors, innovators, and community leaders,” wrote Lesley Collins, HousingWire Editor’s Choice Awards Program Manager. “Many are paving the way for future generations through mentorship, volunteer initiatives, and by serving on boards that influence key industry practices. Collectively, their efforts are shaping not only their companies but also the communities they serve and the future of housing itself.”

Courtney Thompson, EVP of Servicing at CMG, has spent the past year tackling one of the biggest challenges in mortgage servicing: building a modern, borrower-first platform from the ground up. Tasked with developing a fully in-house servicing solution, she’s led a bold effort to move beyond outdated legacy systems and create something built for today’s consumer. Under her leadership, the platform has taken shape as a fully connected ecosystem-one that keeps loan officers involved post-close, gives borrowers access to personalized tools and insights, and reshapes how homeowners interact with their loans. It’s not just a tech project-it’s a reinvention of the servicing experience, and it’s already drawing attention across the industry.

Susan Walker, EVP of Corporate Efficiency at CMG, has spent the past year acting as the voice of the loan officer, translating feedback from top performers into meaningful enhancements to CMG’s core platforms, CLEAR and Byte. By embedding herself directly with Product and Technology teams, she helped identify workflow inefficiencies and delivered rapid-fire improvements that drove adoption, boosted morale, and aided in bolstering these systems into competitive strengths. Her impact earned her a seat on the Executive Management Team, where she now oversees Post Closing, Vendor Management, and Product. In this new role, she continues to lead with the same hands-on, cross-functional approach, streamlining operations, reducing costs, and identifying upstream efficiency and alignment opportunities. Her results speak volumes: a West Division that topped $3B in volume, over 100 strategic hires, and a culture that now embraces technology more than ever before. Susan’s work isn’t just about optimizing systems, it’s about building a smarter, more resilient CMG.

“Courtney and Susan are both exceptional leaders and trusted partners who bring passion, clarity, and a deep sense of responsibility to everything they do,” said Paul Akinmade, Chief Strategy Officer at CMG Financial. “They care deeply about their work, their teams, and the future of this company. What stands out is how they bring people together to drive meaningful change, from the first moments of origination all the way through to servicing.”

CMG congratulates both honorees and thanks HousingWire for recognizing the leadership, excellence, and trailblazing impact of women across housing finance. To read their full Women of Influence profiles, click here.

About CMG

CMG Mortgage, Inc. NMLS ID# 1820 (www.nmlsconsumeraccess.org)(http://www.cmghomeloans.com ) is a well-capitalized mortgage lender founded in 1993. Founder and CEO, Christopher M. George, was Chairman of the Mortgage Bankers Association in 2019. CMG makes its products and services available to the market through three distinct origination channels including retail lending, wholesale lending, and correspondent lending. CMG currently operates in all states, including the District of Columbia, and holds approvals with FNMA, FHLMC, and GNMA. CMG is widely known throughout the mortgage banking and housing markets for responsible lending practices, industry and consumer advocacy, product innovation, and operational efficiency.

About HousingWire

HousingWire is the most influential source of news and information for the U.S. mortgage and housing markets, boasting a readership that spans lending, servicing, investments, and real estate market participants, as well as financial market professionals. With over 10 million annual unique visitors, HousingWire is the community for mortgage and housing professionals to engage and connect. Industry decision-makers rely on us to Move Markets Forward.

Media Contact

Annaugh Madsen
Phone: (667) 260-6360
Email: amadsen@cmgfi.com

SOURCE: CMG Financial

View the original press release on ACCESS Newswire

Leading Online Legal Publication Expands Public Notice Section

HIGHLAND PARK, IL / ACCESS Newswire / July 2, 2025 / The National Law Review® (NLR) is pleased to announce the launch of its National Public Notice Service^TM (NPNS).

Building on the decade of experience its DailyDAC^TM affiliate has in providing public notice of distressed asset sales, NLR’s new National Public Notice Service is now accepting public notices in all legal and regulatory contexts requiring a party to publish a public notice.

“Customer demand is what drove the move,” according to NLR CEO Gary Chodes, “many law firms DailyDACworks with asked it to step in to fill the void left by the continuing closure of traditional print newspapers, and DailyDAC asked NLR to step in.”

Examples of public notices NLR’s National Public Notice Service offers to publish include:

• Abandonment of property

• Class actions

• Distressed asset sales (including assignments for the benefit of creditors, bankruptcies, receiverships, and sales under Article 9 of the UCC)

• Elections

• Formation and dissolution of legal entities

• Land use and zoning matters

• Name changes

• Probate matters

• Public bidding for government contracts

• Public hearings

• Service by publication when a party to a lawsuit cannot be located for personal service

• Tax lien sales

Media Contact:
Billy Thieme, Communications Director
(708) 357-3317
publicnotices@natlawreview.com

About NLR
The National Law Review® is an online legal news and information source with a monthly reach of more than 3 million visitors and newsletter subscribers. It is the online descendant of a business law publication founded in 1888.

SOURCE: The National Law Review

View the original press release on ACCESS Newswire

Breakthrough bioconvergence platform detects inflammatory events prior to symptoms, partnering with Altesa Biosciences to transform care

MONTRÉAL, QUEBEC / ACCESS Newswire / July 2, 2025 / A peer-reviewed study published today in The Lancet Digital Health validates Sensifai’s AI platform as the world’s first wearable-powered system to predict acute inflammation with 90% sensitivity. The technology, which analyzes passive biometric data from off-the-shelf wearables, could prevent many hospitalizations in high-risk patients, such as people experiencing COPD (US COPD costs: $50B annually). Led by Drs. Amir Hadid, Dennis Jensen, and Emily McDonald, the study was conducted at McGill University and the Research Institute of the McGill University Health Center.

Dr. Alan Forster, Director of Innovation, Quality, and Performance at the McGill University Health Centre (MUHC) and the Research Institute of the MUHC (RI-MUHC):

“An often promoted but rarely realized goal is to deliver the right medication to the right patient at the right time. Sensifai’s early detection technology is a promising solution to address this gap. As exemplified by Sensifai, the MUHC is creating conditions, for care providers and companies, to develop AI-based tools to improve the lives of our patients, in Quebec and beyond.”

Dr. Amir Hadid, CEO of Sensifai:

“This isn’t just about early detection. It’s about our ability to widen the therapeutic window and deliver potentially life-saving intervention days before the onset of symptoms. Our study results suggest that merging immunology, physiology, wearables, and AI allows us to usher in a new era of preemptive health.”

Dr. Brett Giroir, CEO of Altesa BioSciences and former US Assistant Secretary for Health and former Acting FDA Commissioner:

“These findings lay the foundation for a new paradigm of prevention and treatment that moves us upstream to intervene before health crises occur. Sensifai’s objectives align perfectly with our mission to deliver transformative respiratory therapeutics at a time when they can be most effective.”

Key Study Insights:

• Novel, personalized inflammation score was developed

• AI algorithm demonstrating 90% sensitivity in predicting inflammatory events, outperforming symptom-based detection.

• 2B+ data points from off-the-shelf wearables, no needles, no extra hardware.

• A noninvasive approach leveraging wearables to enable rapid, objective early warning of viral respiratory infections.

• Helps improve surveillance, reduce transmission, and guide timely interventions, even prior to symptoms emerging.

• For high-risk patients, such as people with COPD, this technology could help prevent exacerbations, decrease hospitalizations, and save lives.

Funding Note: Sensifai recently secured seed funding led by Glen Ventures with major participation by Eurêka investment fund.

About Sensifai Health Inc.

Sensifai Health is a Canadian-Israeli Preemptive Health startup at the forefront of bioconvergence. Its AI-powered platform continuously analyzes data from wearable biometric sensors to deliver early alerts of systemic inflammation before symptoms appear. By identifying silent immune signals in vulnerable individuals, Sensifai enables timely intervention that helps prevent critical health events, reduce hospitalizations, and improve long-term outcomes.

About Altesa BioSciences, Inc.

Altesa BioSciences is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those with chronic health conditions, like lung diseases, as well as the elderly and many people in underserved communities.

About Glen Ventures

Glen Ventures is a health tech-focused early-stage venture capital firm that partners with world-class entrepreneurs to bring transformative healthcare innovations to market. Combining medical insight with operational know-how, Glen Ventures takes an active role in shaping the success of startups at the intersection of science, technology, and care delivery.

About Eurêka investment fund

Eurêka is a Quebec-based investment fund dedicated to catalyzing the growth of innovative companies emerging from Quebec public research. The fund plays a strategic role in bridging the gap between discovery and commercialization to maximize economic and societal returns. The Fund is managed and administered by Investissement Québec, with funding provided by the Québec government through the Fonds du développement économique du Québec.

Download Study: https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00068-8/fulltext

Website: www.sensifai.health

SOURCE: Sensifai Health

View the original press release on ACCESS Newswire

LAFAYETTE, LA / ACCESS Newswire / July 2, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ: VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has completed the previously disclosed acquisition of Illinois-based Lehan’s Medical Equipment (“Lehan”) for a base purchase price of $26 million, subject to customary adjustments, plus estimated contingent payments of $2.2 million.

“We are pleased to close the acquisition of Lehan and bring this talented and highly motivated team into the Viemed family,” said Viemed Chief Executive Officer Casey Hoyt. “Lehan’s 80-year track record and brand recognition in a large and fast-growing market along with its preferred contracts and fulfillment expertise make for a powerful combination with our national scale, unique care delivery model and existing payer relationships to serve a broader patient population.”

In 2024, Lehan generated net revenues of approximately $25.7 million and Adjusted EBITDA of approximately $7.4 million. See “Non-GAAP Financial Measures” for a discussion of Adjusted EBITDA. Viemed funded the acquisition through a combination of cash on hand and borrowings from its existing credit facilities. Viemed anticipates increasing its previously issued full-year 2025 guidance range to account for the expected contribution from this acquisition when it reports earnings results for the quarter ended June 30, 2025.

Lehan’s Medical Equipment is a healthcare provider offering home medical equipment and products for women’s health, including breast pumps. The organization specializes in promoting wellness through a variety of healthcare services. Lehan also provides rental, sales, and resupply of CPAPs and other respiratory devices, as well as sales of other medical equipment. Lehan currently has three full-service locations in the Northern Illinois area and three sleep/CPAP set up locations in the West Chicagoland area, including one in Wisconsin.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.

For further information, please contact:

Investor Relations
ir@viemed.com

Tripp Sullivan
SCR Partners, LLC
615-942-7077

Trae Fitzgerald
Chief Financial Officer
Viemed Healthcare, Inc.
337-504-3802

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company’s expectations about its acquisition of Lehan’s Medical Equipment, such as contingent payments, anticipated benefits, and anticipated updates to the Company’s 2025 financial guidance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

Non-GAAP Financial Measures

This press release refers to “Adjusted EBITDA” which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company’s presentation of Adjusted EBITDA may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and other adjustments, including adjustments relating to the proposed acquisition of Lehan. Company management believes Adjusted EBITDA provides helpful information to analyze Lehan’s operating performance, including a view of Lehan’s business that is not dependent on the impact of Lehan’s capitalization structure and the exclusion of items that are not part of Lehan’s recurring operations, including the impacts of the Company’s proposed acquisition of Lehan. Accordingly, Company management believes that Adjusted EBITDA provides useful information in understanding and evaluating Lehan’s historical operating performance in the same manner as it analyzes the Company’s operating performance.

SOURCE: Viemed Healthcare, Inc.

View the original press release on ACCESS Newswire

Safety Strips launches direct-to-consumer e-commerce store to expand access to its ToxiShield brand of test strips designed to combat fentanyl overdoses and drink spiking

Greenlane empowers brands and retailers under one platform, leveraging powerful automation, compliance, and fulfillment tools

BOCA RATON, FL / ACCESS Newswire / July 2, 2025 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq:GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced it will serve as the exclusive fulfillment platform for Safety Strips Tech Corp. (“Safety Strips”) direct-to-consumer e-commerce store featuring ToxiShield, the company’s trusted brand of harm reduction solutions designed to combat fentanyl overdoses and drink spiking.

The agreement to fulfill Safety Strips direct-to-consumer e-commerce orders follows Greenlane’s previously announced exclusive multi-year distribution agreement with Safety Strips to distribute their fentanyl, xylazine and drink spike detection test strips in the U.S. via the Company’s multiple online retail storefronts, as well as its wholesale portal.

Safety Strips is committed to increasing accessibility to rapid drug testing and harm reduction technologies, particularly fentanyl and drink spiking test strips, across North America. The new e-commerce store features the full line of ToxiShield products and allows individuals, organizations, and community groups to easily purchase Safety Strips’ innovative products online, furthering harm reduction efforts in both public and private settings.

“With two decades of industry experience and a focus on innovation, Greenlane is well-positioned to meet the needs of customers in the high-demand market for harm reduction solutions. Our team is dedicated to helping customers improve their supply chain at all levels and we are excited to be working with Safety Strips to deliver their safe and compliant high-quality test strip products to their customers,” said Barbara Sher, Chief Executive Officer for Greenlane.

This agreement recognizes Greenlane’s well established distribution capabilities and technology infrastructure to enable businesses of all sizes to streamline fulfillment and grow efficiently. Additionally, this initiative is consistent with Greenlane’s ongoing product diversification initiatives designed to offer its customers a broader array of premium health, safety and wellness products.

About Safety Strips Tech Corp.

Safety Strips Tech Corp., a wholly owned subsidiary of Safe Supply Streaming Co Ltd., develops and commercializes innovative harm reduction tools, including proprietary fentanyl detection kits and drink spike test kits, providing individuals and communities with critical protections in a discreet, affordable format.

Visit the new store at: www.toxishield.com

About Greenlane Holdings, Inc.

Founded in 2005, Greenlane is a premier global platform for the development and distribution of premium smoking accessories, vape devices, and lifestyle products to thousands of producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. We operate as a powerful family of brands, third-party brand accelerator, and an omnichannel distribution platform.

We proudly offer our own diverse brand portfolio and our exclusively licensed Marley Natural and K. Haring branded products. We also offer a carefully curated set of third-party products through our direct sales channels and our proprietary, owned and operated e-commerce platforms which include Vapor.com, , PuffItUp.com, HigherStandards.com, Wholesale.Greenlane.com and MarleyNaturalShop.com.

For additional information, please visit: https://investor.gnln.com. For additional information, please visit: https://gnln.com/.

Investor Contact:

IR@greenlane.com

or

TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Greenlane and other matters. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Greenlane has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including those described in our filings with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in Greenlane’s Annual Report on Form 10-K filed for the year ended December 31, 2023 and the Company’s other filings with the SEC, which can be obtained on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the SEC.

SOURCE: Greenlane Holdings, Inc.

View the original press release on ACCESS Newswire